Reproductive Health Ovarian Damage During Chemotherapy In
Total Page:16
File Type:pdf, Size:1020Kb
Clinical Medicine Insights: Reproductive Health OPEN ACCESS Full open access to this and thousands of other papers at PErspEctiVE http://www.la-press.com. Ovarian Damage During Chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility Wendy Marder1, Senait Fisseha2, Martha A. Ganser1 and Emily C. Somers1–3 1Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA. 2Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Michigan, Ann Arbor, Michigan, USA. 3Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, USA. Corresponding author email: [email protected] Abstract: Women with autoimmune diseases such as lupus, scleroderma, and vasculitis receiving cyclophosphamide for severe disease manifestations risk primary ovarian insufficiency (POI) due to gonadotoxicity of this therapy. In addition to loss of reproductive poten- tial, POI is associated with increased risk of morbidity and mortality. Practitioners caring for women requiring gonadotoxic therapies should be familiar with long-term health implications of POI and strategies for ovarian preservation. Accumulating evidence supports the effectiveness of adjunctive gonadotropin releasing hormone analog (GnRH-a) for ovarian protection during gonadotoxic therapy in cancer and autoimmune populations. GnRH-a is less costly and invasive than assisted reproductive technologies used for achieve- ment of future pregnancies, but is not Food and Drug Administration approved for ovarian preservation. This review focuses on POI comorbidities and strategies for mitigation of related sequelae, which can accumulate over decades of hypoesteogenism. These issues are arguably more pronounced for women with chronic autoimmune diseases, in whom superimposed POI further heightens risks of car- diovascular disease and osteoporosis. Therefore, even if future pregnancy is not desired, ovarian protection during gonadotoxic therapy should be a major goal of disease management. Keywords: primary ovarian insufficiency, autoimmune diseases, cyclophosphamide, fertility preservation Clinical Medicine Insights: Reproductive Health 2012:6 9–18 doi: 10.4137/CMRH.S10415 This article is available from http://www.la-press.com. © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. Clinical Medicine Insights: Reproductive Health 2012:6 9 Marder et al Introduction least 1 month apart in the menopausal range.5 Unlike Severe manifestations of autoimmune diseases, such natural menopause, which occurs on average at age as systemic lupus erythematosus (SLE), systemic 50 years,12 50% of women with POI still have varia- sclerosis, and vasculitis, often require treatment tions in ovarian function, and 5%–10% conceive and with gonadotoxic immunosuppressive medications, deliver a child after receiving the diagnosis.5,13,14 particularly cyclophosphamide (CYC). While CYC While sequelae apply to all causes of POI (which is administration prolongs survival in these diseases, most frequently considered to be idiopathic, affecting it is associated with significant toxicity, including 1% of women under the age of 40 years),15,16 symptoms an unacceptably high incidence of primary ovarian are compounded in women with autoimmune diseases. insufficiency (POI) in female patients, with con- Both the underlying autoimmune/inflammatory pro- sequent irreversible amenorrhea and infertility.1–3 cesses and their treatments (eg, corticosteroids) are Beyond reproductive implications, POI is associated associated with many serious long-term consequences with broad and long lasting detrimental effects on of hypoestrogenism, most notably cardiovascular dis- general health, quality of life, and life expectancy.4–6 ease and loss of bone mineral density.17–21 These poten- With autoimmune diseases often affecting women tial long-term consequences of ovarian damage, beyond during their reproductive years,7 it is imperative that infertility, may be overlooked in women with autoim- the risks of prolonged hypoestrogenemia associated mune diseases requiring CYC (often on an urgent or with gonadotoxic therapies are adequately recog- semi-urgent basis), and particularly among patients nized when formulating treatment plans. These issues who may not be concerned with future childbearing. have been rigorously addressed in the field of oncol- ogy, as is evidenced by the development of practice Medications used in Autoimmune guidelines for fertility preservation in the cancer Diseases Associated with POI population.8 In comparison, rheumatologists have and Common Sequelae yet to develop similar practice guidelines for fertility Alkylating agents preservation in rheumatic disease patients undergo- Alkylating agents such as CYC and chlorambucil are ing treatment with gonadotoxic chemotherapy. immunosuppressive medications used to treat severe In this broad overview, we aim to: (a) increase manifestations of autoimmune diseases, including awareness and understanding of potential health con- SLE, systemic sclerosis, and vasculitis, and they are sequences, beyond infertility, of gonadotoxic therapies used as part of chemotherapeutic regimens for both in young women; and (b) highlight potential strategies hematologic malignancies and solid tumors. Even as for mitigation of such risks and resulting comorbidi- potentially less toxic alternatives for CYC therapy ties, including methods for ovarian protection. become more widely applied (eg, mycophenolate mofetil),22,23 CYC is still indicated in patients with Triple Threat of Primary Ovarian organ-threatening manifestations of severe autoim- Insufficiency, Underlying Autoimmune mune disease. In humans, CYC-induced ovarian Disease, and Treatment Side Effects damage is generally regarded as cumulative and irre- Menopause before the age of 40 years is considered versible, due in part to the progressive reduction of to be premature.5 The term “primary ovarian insuf- a limited number of primordial follicles.1–3 Among ficiency,” rather than “primary ovarian failure” or female patients treated with CYC for rheumatic dis- “premature menopause,” is the currently preferred ease or malignancy, POI develops in 12% to 83%, term, as it is less stigmatizing and allows the condition depending on variables including patient age, mode to be viewed as a continuum of impaired ovarian func- of administration, and cumulative CYC dose, all of tion as opposed to a dichotomous state.9–11 POI has which are strong predictors of POI.2,3,24–27 CYC may become recognized as “a serious and incurable chronic also contribute directly to bone loss, even beyond its disease,” the diagnosis of which requires a woman to potential to induce a hypoestrongenic state.28,29 In ani- be less than 40 years old, have experienced amenor- mal models, CYC decreases the number of osteoclasts rhea for 4 months or more, and she has to have two and osteoblasts on bone surfaces, and exerts adverse serum follicle stimulating hormone levels obtained at effects on epiphyseal growth plates.30,31 10 Clinical Medicine Insights: Reproductive Health 2012:6 Primary ovarian insufficiency in autoimmune disease Glucocorticoids at an age greater than 50 years.4,46 Similarly, mortality Large cumulative doses of glucocorticoid therapy has been shown to be significantly higher in women (GC), either by intravenous bolus dosing or through who undergo oophorectomy before age 45 versus prolonged daily oral therapy, have been associated referent women.47 Recently, prospective data from with side effects including accelerated atherosclero- a large, homogenous population-based study evalu- sis and osteoporosis.20,21,32–35 Although glucocorticoid ating the risk of fracture and mortality associated therapy is a cornerstone of treatment for patients with with age at menopause revealed that at 34 years of autoimmune diseases, efforts are continually being follow-up, women undergoing menopause before age made to decrease cumulative exposure by maintain- 47 had increased risks of mortality, fragility fractures, ing patients on immunosuppressive “steroid-sparing” and osteoporosis at age 77.48 agents such as methotrexate, azathioprine, and myco- phenolate mofetil. At high intravenous doses (eg, Cardiovascular disease .250 mg), the most common immediate side effects POI of any cause may also be associated with increased of glucocorticoid therapy include elevation of dia- morbidity and mortality from cardiovascular disease stolic blood pressure, cardiac arrhythmia, hyperglyce- (CVD) due to premature loss of the protective effects mia, and flushing.36 Long-term, moderate daily doses of estrogen.45,46 Data from several large cohort studies of prednisone, defined as .7.5 mg to 30 mg a day confirm the presence of a heightened CVD risk among for more than 2–3 months are associated with a range women who had a bilateral oophorectomy before age of adverse outcomes, including myopathy, glaucoma, 40 compared to after age 45, and the effect of exog- cataracts, infections, avascular necrosis, weight gain, enous estrogen was not necessarily protective.49,50 and various mood disturbances including depression, The Mayo Clinic Cohort Study of Oophorectomy and anxiety, and even psychosis.37–39 Even at low daily Aging, which included over 2,000 cases of unilateral doses (less than 7.5 mg/day), side effects of gluco-